Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, under the TRICARE Management Activity, issued solicitation HT9402-26-Q-9103 to support the Department of Defense (DoD) Pharmacy Uniform Formulary. Required by 10 U.S.C. § 1074g, this program establishes an integrated pharmacy benefits system for the Military Health System through the purchase of pharmaceutical agents. The opportunity is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 DRUGS AND BIOLOGICALS. The DoD Pharmacy and Therapeutics Committee evaluates the clinical and cost-effectiveness of drugs to determine their placement within the Uniform Formulary as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary agents.

The scope of this solicitation involves the potential award of Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements. The upcoming review cycle focus includes several newly approved drugs: Hyrnuo for lung cancer, Javadin for hypertension, Komzifti for leukemia and lymphoma, Lasix ONYU as a diuretic, Redemplo for antilipidemics, and Starjemza for targeted immunomodulatory biologics. This process allows the Defense Health Agency to obtain quotes from industry participants prior to the scheduled committee meetings where final placement decisions are made.

Responses to this solicitation are due by January 5, 2026. The primary place of performance is San Antonio, Texas, and Tracy Banks serves as the point of contact. The notice includes 12 attachments, such as drug-specific price lists for Komzifti, Starjemza, Redemplo, and Lasix ONYU, as well as the formal Request for Quotation and DoD formulary placement guidelines. A pre-quotation teleconference was scheduled for December 17, 2025, to address the requirements and instructions for clinical question submissions.